CN110114057A - Tlr9激动剂对癌症治疗的免疫调节作用 - Google Patents

Tlr9激动剂对癌症治疗的免疫调节作用 Download PDF

Info

Publication number
CN110114057A
CN110114057A CN201780067972.4A CN201780067972A CN110114057A CN 110114057 A CN110114057 A CN 110114057A CN 201780067972 A CN201780067972 A CN 201780067972A CN 110114057 A CN110114057 A CN 110114057A
Authority
CN
China
Prior art keywords
cancer
imo
tumor
given
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780067972.4A
Other languages
English (en)
Chinese (zh)
Inventor
S.阿拉瓦尔
D.王
W.蒋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Publication of CN110114057A publication Critical patent/CN110114057A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780067972.4A 2016-09-15 2017-09-15 Tlr9激动剂对癌症治疗的免疫调节作用 Pending CN110114057A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394845P 2016-09-15 2016-09-15
US62/394845 2016-09-15
US201762486738P 2017-04-18 2017-04-18
US62/486738 2017-04-18
PCT/US2017/051742 WO2018053242A1 (en) 2016-09-15 2017-09-15 Immune modulation with tlr9 agonists for cancer treatment

Publications (1)

Publication Number Publication Date
CN110114057A true CN110114057A (zh) 2019-08-09

Family

ID=61620152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780067972.4A Pending CN110114057A (zh) 2016-09-15 2017-09-15 Tlr9激动剂对癌症治疗的免疫调节作用

Country Status (10)

Country Link
US (6) US10463686B2 (https=)
EP (1) EP3512499A4 (https=)
JP (2) JP7200093B2 (https=)
KR (1) KR20190096936A (https=)
CN (1) CN110114057A (https=)
AU (1) AU2017325981A1 (https=)
CA (1) CA3036978A1 (https=)
IL (2) IL292658A (https=)
MX (1) MX2019002925A (https=)
WO (1) WO2018053242A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116406276A (zh) * 2020-09-22 2023-07-07 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11643463B2 (en) 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
JP2022512745A (ja) * 2018-10-18 2022-02-07 アイデラ・ファーマシューティカルズ，インコーポレーテッド がんを処置するためのｔｌｒ９調節因子
KR20210087454A (ko) * 2018-11-01 2021-07-12 파론 파머수티컬스 오와이 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제
BR112021012536A2 (pt) 2018-12-26 2021-09-14 City Of Hope Proteínas de ligação anti-ctla4 mascaradas ativáveis
US20230072809A1 (en) * 2020-03-09 2023-03-09 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101693890A (zh) * 2002-12-23 2010-04-14 戴纳伐克斯技术股份有限公司 免疫刺激序列寡核苷酸和使用方法
US20140120088A1 (en) * 2011-05-24 2014-05-01 Assistance Publique-Hopitaux De Paris Agents for the treatment of tumors
CN103957939A (zh) * 2011-09-19 2014-07-30 约翰霍普金斯大学 癌症免疫治疗
US20160101128A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016128542A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1200580T3 (da) 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
JP4188687B2 (ja) 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
MXPA05013658A (es) 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
CN100482673C (zh) 2003-07-15 2009-04-29 艾德拉药物股份有限公司 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用
MXPA06000619A (es) 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US20060014713A1 (en) 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
US7427405B2 (en) 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
JP2009500412A (ja) 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7786089B2 (en) 2005-12-20 2010-08-31 Idera Pharmaceuticals, Inc. Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
MX2009006230A (es) 2006-12-12 2009-06-22 Idera Pharmaceuticals Inc Agonistas sinteticos de receptores de tipo toll 9.
KR20100053598A (ko) 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ９의 신규한 합성 효능제
US20110293565A1 (en) 2009-01-30 2011-12-01 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
EP2533779A4 (en) 2010-02-09 2013-08-21 Georgia Health Sciences University Res Inst Inc ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
CN105163754B (zh) 2012-09-20 2018-01-05 王荣福 前列腺特异性肿瘤抗原及其用途
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
CN107708706A (zh) 2015-05-29 2018-02-16 戴纳瓦克斯技术公司 用于治疗肺的癌症的多核苷酸Toll样受体9激动剂的肺内施用
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101693890A (zh) * 2002-12-23 2010-04-14 戴纳伐克斯技术股份有限公司 免疫刺激序列寡核苷酸和使用方法
US20140120088A1 (en) * 2011-05-24 2014-05-01 Assistance Publique-Hopitaux De Paris Agents for the treatment of tumors
CN103957939A (zh) * 2011-09-19 2014-07-30 约翰霍普金斯大学 癌症免疫治疗
US20160101128A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016128542A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAQING WANG等: "Creating the tumor microenvironment for effective immunotherapy: antitumor activity of intratumoral IMO-2125, a TLR9 agonist, is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)", 《THE AACR ANNUAL MEETING》 *
IDERA PHARMACEUTICALS, INC.: "Idera Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Trial of Intra-tumoral IMO-2125 in Combination With Ipilimumab in Patients With Metastatic Melanoma", 《HTTPS://WWW.GLOBENEWSWIRE.COM/EN/NEWS-RELEASE/2015/12/14/795183/33448/EN/IDERA-PHARMACEUTICALS-ANNOUNCES-INITIATION-OF-PHASE-1-2-CLINICAL-TRIAL-OF-INTRA-TUMORAL-IMO-2125-IN-COMBINATION-WITH-IPILIMUMAB-IN-PATIENTS-WITH-METASTATIC-MELANOMA.HTML》 *
石远凯: "《中国肿瘤内科进展 中国肿瘤医师教育（2015年）》", 31 July 2015, 中国协和医科大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116406276A (zh) * 2020-09-22 2023-07-07 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法

Also Published As

Publication number Publication date
EP3512499A4 (en) 2020-08-05
US20180125877A1 (en) 2018-05-10
US11224611B2 (en) 2022-01-18
US10835550B2 (en) 2020-11-17
JP2022009200A (ja) 2022-01-14
JP2019529415A (ja) 2019-10-17
KR20190096936A (ko) 2019-08-20
IL292658A (en) 2022-07-01
US10772907B2 (en) 2020-09-15
IL265370B (en) 2022-06-01
MX2019002925A (es) 2019-09-05
US20210038630A1 (en) 2021-02-11
JP7200093B2 (ja) 2023-01-06
CA3036978A1 (en) 2018-03-22
US20210052625A1 (en) 2021-02-25
AU2017325981A1 (en) 2019-04-11
WO2018053242A1 (en) 2018-03-22
US20200054663A1 (en) 2020-02-20
EP3512499A1 (en) 2019-07-24
US20220088054A1 (en) 2022-03-24
US10463686B2 (en) 2019-11-05
IL265370A (en) 2019-05-30
US20200138848A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
US11224611B2 (en) Immune modulation with TLR9 agonists for cancer treatment
US20230374503A1 (en) Combination
Queirolo et al. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
KR101820393B1 (ko) 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
US20210299187A1 (en) Cancer therapy
US20240033257A1 (en) Use of ppar-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug
KR20180015269A (ko) 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
Dovedi et al. Emerging targeted therapies for bladder cancer: a disease waiting for a drug
US20250123284A1 (en) Diagnostic methods for cancer using ephrinb2 expression
JP2023539436A (ja) 膵臓癌の評価および処置のための方法および組成物
益田昌吾 Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in Head and Neck Cancer, Especially in Hypoxic Environments
WO2024052674A1 (en) Modified t-cells for use in the treatment of bladder cancer
CN113226366A (zh) 用于治疗癌症的tlr9调节剂
HK1238287A1 (en) Combination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190809

WD01 Invention patent application deemed withdrawn after publication